Article Text

Download PDFPDF

854 Glutamine blockade and anti-PD1 treatment reprograms the tumor infiltrating myeloid cells in mouse model of soft tissue sarcomas
  1. Aditya Suru1,
  2. Alexandre Maalouf2,
  3. Liang Zhao2,
  4. Ada Tam1,
  5. Lindy Zhang3,
  6. Michele Doucet1,
  7. Marwa Islam4,
  8. Zahra Jamil5,
  9. Christian Meyer2,
  10. Carol Morris6,
  11. Adam Levin2,
  12. John Gross6,
  13. Sophia A Strike6,
  14. Jonathan Greer2,
  15. Fabian Johnston1,
  16. Daniel Rhee2,
  17. Brian Ladle2,
  18. Sudipto Ganguly1,
  19. Robert Anders7,
  20. Drew Pardoll1 and
  21. Nicolas Llosa6
  1. 1Johns Hopkins University, Baltimore, MD, USA
  2. 2Johns Hopkins University School of Medicine, Baltimore, MD, USA
  3. 3Johns Hopkins Hospital, Baltimore, MD, USA
  4. 4Macaulay Honors College, New York, NY, USA
  5. 5Brooklyn College, New York, NY, USA
  6. 6Johns Hopkins Medicine, Baltimore, MD, USA
  7. 7Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD, USA
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background Immunotherapy holds great potential to treat cancers such as sarcomas. A major impediment for immune mediated tumor killing in sarcomas is a strong presence of suppressive cell types such as Myeloid Derived Suppressor Cells (MDSC) dominating the Tumor Immune Micro-Environment (TIME) and a dearth of effector cell types such as T Cells.1 Cellular metabolism has emerged as a novel checkpoint to modulate immune responses by targeting various metabolic pathways. Glutamine is a key metabolite participating in the TCA cycle and is implicated in sarcoma-genesis2 and its blockade has shown to skew immune cell function and phenotype.3 We used JHU083, a novel prodrug of a glutamine antagonist (6-Diazo-5-oxo-L-norleucine) to rid the TME of glutamine and interrogate its downstream effects on the TIME.

Methods Cells derived from primary tumors from LSL-KrasG12D/+ p53flox/flox mice (KP Cells)4 were subcutaneously injected in C57BL/6J mice. The mice were treated with JHU083 (1mg/kg on days 7–11 and 0.3mg/kg daily till end) and anti-PD1 monoclonal antibody (100ug on days 7, 9, 11 and 13) or saline and euthanized at Day 20. We studied the 3 major tumor infiltrating myeloid cells, namely, Monocytic MDSC, Granulocytic MDSC (GMDSC) and Macrophages by flow cytometry and FACS sorted them to profile their transcriptome using NanoString Mouse Myeloid Innate Immunity Panel.

Results The combination treated group had significantly less tumor burden at the end of Day 20 than the control group. We saw a significant reduction in the percentage of GMDSC in the combination treated group. We observed a consistent reduction in expression of Csf3 and Csf3r and an upregulation of complement related genes specifically C1qa, C1qb and C1qc across the three subsets in the treated group. Transcriptionally, the most affected cell type was the GMDSC subset which saw an upregulation of Apoe and other genes such as Acly, Calr, Pf4, Grn, Trem2 upon glutamine blockade. These genes are known to be expressed in a subset of myeloid cells in multiple human cancers.5

Conclusions Combination of glutamine blockade and anti-PD1 therapy can be an effective strategy to modulate myeloid cell frequency and phenotype in this model of soft tissue sarcomas. Transcriptional changes upon glutamine blockade, especially upregulation of Apoe, a key apolipoprotein implicated in cholesterol transport points towards rewiring of metabolism of the myeloid cells. This hints that the heterogenous metabolome/lipidome might hold clues to the differential responses to glutamine blockade in the myeloid subsets.


  1. L Chen. The Immunosuppressive Niche of Soft-Tissue Sarcomas is Sustained by Tumor-Associated Macrophages and Characterized by Intratumoral Tertiary Lymphoid Structures, Clinical Cancer Research, 26:4018–4030

  2. Lee P, Malik D, Perkons N, et al. Targeting glutamine metabolism slows soft tissue sarcoma growth. Nat Commun 2020;11:498.

  3. Min-Hee Oh. Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells. J Clin Invest. 2020;130(7):3865–3884

  4. D Kirsch. A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat Med. 2007 Aug;13(8):992–7

  5. RY Ma. Macrophage diversity in cancer revisited in the era of single-cell omics. Trends in Immunology. July 2022;43(7):546–563.

Ethics Approval All animal procedures performed were approved by the Johns Hopkins University Animal Care Committee.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.